Scott A Cohen

Title: Scott A Cohen: Innovator in Biomarker Detection for Sepsis Encephalopathy

Introduction

Scott A Cohen is a notable inventor based in Gainesville, FL (US). He has made significant contributions to the field of medical diagnostics, particularly in the detection of biomarkers associated with sepsis-associated encephalopathy (SAE). His innovative work aims to improve patient outcomes through early diagnosis and assessment.

Latest Patents

Scott A Cohen holds a patent for a "Biomarker panel for sepsis encephalopathy." This invention provides methods for detecting various biomarkers in the biofluid of SAE patients. The biomarkers include glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase LI, Tan protein, Neurofilament light chain (NF-L), myelin basic protein (MBP), secretogranin, Copeptin, total all-spectrin, and neuron specific enolase (NSE), among others. These biomarker peptides serve as indicators of axonal and blood-brain barrier integrity, which can be crucial for diagnosing SAE and predicting cognitive performance in acute sepsis cases. Scott A Cohen has 1 patent to his name.

Career Highlights

Scott A Cohen is affiliated with the University of Florida Research Foundation Inc., where he continues to advance his research in biomarker detection. His work is pivotal in enhancing the understanding of sepsis and its neurological implications.

Collaborations

Scott has collaborated with esteemed colleagues such as Marie C Elie and Zhihui Yang, contributing to the advancement of research in his field.

Conclusion

Scott A Cohen's innovative contributions to the detection of biomarkers for sepsis-associated encephalopathy highlight his commitment to improving medical diagnostics. His work not only aids in early diagnosis but also enhances the understanding of cognitive outcomes in sepsis patients.